In a report released on April 29, Marc Goodman from Leerink Partners maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $8.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Marc Goodman has given his Hold rating due to a combination of factors related to SAGE Therapeutics’ recent performance and future prospects. The company’s reported collaboration revenue for Zurzuvae in postpartum depression was approximately $14 million, aligning with market expectations and indicating steady growth. This revenue, alongside the expansion of their sales force and increased marketing efforts, suggests a positive trajectory but not enough to warrant a more aggressive rating.
Additionally, while there are promising developments in the pipeline, such as the anticipated updates on SAGE-324 and ongoing strategic evaluations by the Board of Directors, these factors are still in early stages and carry inherent uncertainties. The company’s financial position, with around $400 million in cash expected to sustain operations into mid-2027, provides a stable foundation but does not significantly alter the risk profile. Consequently, Goodman maintains a Hold rating, reflecting a balanced view of potential risks and rewards.